Speaker: Base AMD treatment decisions on available medical evidence

KOLOA, Hawaii — As-needed administration of anti-VEGF provides durable results with less frequent dosing, a speaker said here, and ‘one dosing regimen does not fit all patients.’ “Today in 2014, there are many AMD treatments to choose – ranibizumab, bevacizumab and aflibercept. How do we choose?” Diana V. Do, MD, Director of the Truhlsen Eye Institute in Omaha, Nebraska, asked at Retina 2014.

Full Story →